Could a diabetes pill help you breathe better at night?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to provide informed consent and stated willingness to comply with all study procedures and availability for the duration of the study * Overweight or obese (body mass index 25-40 kg/m2) * Clinically confirmed diagnosis of obstructive sleep apnea by one of the following methods: a. Polysomnography: AHI ≥15/hour sleep or b. Home sleep apnea testing: Respiratory event index (REI) ≥15/hour sleep * AHI: apnea-hypopnea index (apneas + hypopneas / total sleep time in hours) Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: * Known non-OSA related conditions associated with sleep disordered breathing (e.g., central disorder of hypersomnolence, neurological, neuromuscular, or pulmonary disorder) * Use of sleep-inducing medications (e.g. benzodiazepines, opiates, barbiturates) * Type 1 diabetes mellitus * History of diabetic ketoacidosis * Known hypersensitivity reaction to bexagliflozin or any of its constituents or any contraindication to bexagliflozin use * Severe, recurrent urinary tract or genital mycotic infections * eGFR\<30mL/min/1.73m2 at time of or within 4 weeks of enrollment in the study * Unable to complete/tolerate magnetic resonance imaging (MRI) due to severe claustrophobia or metallic implants. * Language barrier, mental incapacity, unwillingness or inability to understand. * Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant. * Currently or planning to take a SGLT2i prior to or during enrollment in the study * Currently or planning to follow a ketogenic diet pattern ("keto diet) prior to or during enrollment in the study * Currently or planning to follow an active weight loss program (including but not limited to use of supplements, medications, or surgery) prior to or during enrollment in the study * Currently or planning to follow an intermittent fasting diet plan prior to or during enrollment in the study * Currently or planning to take a GLP-1 receptor agonist prior to or during enrollment in the study . * Existing lower limb ulcer (due to diabetes or any cause) * Existing severe peripheral arterial disease with intermittent claudication and/or prior lower limb revascularization procedure * Concomitant administration of UGT inducers * Severe liver disease